维生素A注射预防支气管肺发育不良或死亡应保留给高危婴儿吗?
该研究对1996-1997年美国14个NICU的随机对照试验进行事后再分析,纳入出生体重401-1000g且24小时龄需呼吸支持的婴儿,比较肌注维生素A 5000IU每周3次共4周与假操作。结果显示维生素A组BPD或死亡风险降低(RR 0.89),且效果随预测风险降低而增大,低风险婴儿获益更大。
要点
- 维生素A降低BPD或死亡风险(RR 0.89,95%CI 0.80-0.99)。
- 预测风险25%时RR 0.73,75%时RR 0.96。
核心结论
- 与预期相反,维生素A对BPD或死亡的效果在较低风险婴儿中比较高风险婴儿更大。
研究设计与样本
- 对1996年1月至1997年7月在美国14个大学附属NICU开展的III期随机对照试验进行事后再分析。
- 纳入出生体重401-1000g且24小时龄接受呼吸支持的婴儿,随机接受肌注维生素A 5000IU或假操作,每周3次共4周。
主要发现
- 维生素A组405例中222例(54.8%)发生BPD或死亡,对照组402例中248例(61.7%)发生(RR 0.89,95%CI 0.80-0.99;RD -6.9%,95%CI -13.0至-0.7)。
- 预测个体BPD或死亡风险范围为7.1%至98.6%(中位数61.5%,均值60.9%)。
- 各风险组间维生素A缺乏的改善无差异。
临床怎么用
- 维生素A预防BPD或死亡的效果在低风险婴儿中更明显,不支持仅限高危婴儿使用。
局限性
- 本研究为事后再分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether infants at higher risk of bronchopulmonary dysplasia (BPD) or death benefit more from vitamin A therapy than those at lower risk. STUDY DESIGN: We conducted a post hoc reanalysis of a landmark phase III randomized controlled trial conducted from January 1996 to July 1997 at 14 university-affiliated neonatal intensive care units in the US. Data analysis was performed from October 2019 to October 2020. Infants born weighing 401-1000 g and receiving respiratory support at 24 hours of age were assigned to intramuscular vitamin A 5000 IU or sham procedure 3 times weekly for 4 weeks. The primary outcome was BPD, defined as use of supplemental oxygen, or death at 36 weeks postmenstrual age. An externally validated model for predicting BPD or death was used to estimate the risk of these outcomes for each infant. RESULTS: As previously reported, 222 of 405 infants (54.8%) assigned vitamin A therapy and 248 of 402 infants (61.7%) in the control group developed BPD or died (relative risk [RR], 0.89 [95% CI, 0.80-0.99]; risk difference [RD], -6.9% [95% CI, -13.0 to -0.7]). The predicted individual risks of BPD or death ranged from 7.1% to 98.6% (median, 61.5%; mean, 60.9%). The effect of vitamin A therapy on BPD or death depended on infants' risk of the primary outcome (P = .03 for interaction): for example, a RR of 0.73 (RD, -14.5%) for infants with a 25% predicted risk and a RR of 0.96 (RD, -1.0%) for infants with a 75% risk. There was no difference in the decrease in vitamin A deficiency across risk groups. CONCLUSIONS: Contrary to expectations, the effect of vitamin A therapy on BPD or death was greater for lower risk than higher risk infants. TRIAL REGISTRATION: ClinicalTrials.gov NCT01203488.
引用
- Rysavy MA, Li L, Tyson JE, et al. Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial. J Pediatr. 2021. PMID: 34004189. doi:10.1016/j.jpeds.2021.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。